(Gastric Cancer) Is Pembrolizumab Plus Lenvatinib Effective?
Medical Supporter — Avis d’information
Cet article est une synthèse d’informations médicales internationales et ne constitue pas un avis médical ; il ne remplace pas le diagnostic ni le plan de traitement de votre médecin traitant. Les informations présentées sont compilées à partir de publications publiques et de déclarations officielles d’établissements médicaux japonais ; l’adéquation et les résultats de toute thérapie varient selon chaque patient et doivent être évalués individuellement par un médecin qualifié.
- July 20, 2020
- Reading time: 2 minutes
On June 23, 2020, Akihito Kawazoe published in the medical journal The Lancet the EPOC1706 Phase 2 trial results verifying the efficacy and safety of first-line pembrolizumab (Keytruda) plus lenvatinib — a multikinase tyrosine kinase inhibitor — in patients with advanced gastric cancer.
Trial Design
This Phase 2 trial enrolled 29 patients with advanced gastric cancer and administered pembrolizumab (200 mg, 3-week cycles) plus lenvatinib (20 mg once daily) as first-line treatment. The primary endpoint was objective response rate (ORR). Secondary endpoints included adverse event rate, progression-free survival (PFS), and overall survival (OS).
Background: Anti-PD-1 antibody pembrolizumab alone achieves approximately 15% antitumor activity in advanced gastric cancer. Preclinical results confirmed that combining a multikinase tyrosine kinase inhibitor lenvatinib with an anti-PD-1 antibody enhanced antitumor efficacy, providing the rationale for this trial.
Efficacy Results
At a median follow-up of 12.6 months, the primary endpoint ORR was 69%.
Safety Profile
Grade 3 adverse events confirmed in most patients:
- Hypertension: 38%
- Proteinuria: 17%
- Thrombocytopenia: 7%
No patient deaths due to adverse events were confirmed.
Conclusions
Based on the Phase 2 trial results, Akihito Kawazoe concluded that first-line pembrolizumab plus lenvatinib in patients with advanced gastric cancer demonstrated sufficient antitumor activity with acceptable tolerability.
Source: Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial. Lancet Oncol. 2020 Jun 23.
- Clinical trial drug
- Immunotherapy
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Vous envisagez des soins au Japon ? Besoin d’informations et d’aide ?
Nous vous aidons à rassembler les informations nécessaires pour un déplacement médical au Japon, à contacter les établissements japonais et à organiser une consultation de second avis.La première consultation est gratuite ; un conseiller vous aide à clarifier les prochaines étapes.
Figure 1
Figure 2
Figure 3
Figure 4